SRMRC has achieved a new success in a study looking at a potentially life saving treatment for patients with head injuries.
The SyNAPSe trial, which is overseen globally by American pharmaceutical company BHR Pharma, looks at the use of a hormone called progesterone to protect delicate brain cells from damage caused by inflammation.
QEHB was the first centre in the world to meet BHR Pharma’s Find Five! target of recruiting five patients after November 1, and the hospital is now the equal eighth highest recruiter overall with 15 patients enrolled in the study overall.
The trial is run at QEHB by the NIHR Surgical Reconstruction and Microbiology Research Centre, a national centre for trauma research, taking discoveries from the military frontline to improve outcomes for all patients in the UK. The Principle Investigator is Dr Mav Manji, and recruitment has been carried out in close collaboration with the hospital’s Emergency Department and Critical Care wards.
As a result of this success, QEHB is hosting a recruitment summit for all the UK SyNAPSe centres in February to help increase overall recruitment rates.
